The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4−CD8− Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus
Open accessAbstract
The mechanistic target of rapamycin (mTOR) is activated in CD4−CD8− double-negative (DN) T cells and its blockade is therapeutic in systemic lupus erythematosus (SLE) patients. Murine studies showed the involvement of mTOR complex 1 (mTORC1) and 2 (mTORC2) in the differentiation of Th1/Th17 cells and Th2 cells, respectively. In this study, we investigated the roles of mTORC1 and mTORC2 in T cell lineage development in SLE and matched healthy control (HC) subjects. mTORC1 activity was increased, whereas mTORC2 was reduced, as assessed by phosphorylation of their substrates phosphorylated S6 kinase 1 or phosphorylated S6 ribosomal protein and phosphorylated Akt, respectively. Rapamycin inhibited mTORC1 and enhanced mTORC2. IL-4 expression was increased in freshly isolated CD8+ lupus T cells (SLE: 8.09 ± 1.93%, HC: 3.61 ± 0.49%; p = 0.01). DN T cells had greater IL-4 expression than CD4+ or CD8+ T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 ± 1.48%, rapamycin: 5.03 ± 0.66%; p < 0.001). GATA-3 expression was increased in CD8+ lupus T cells (p < 0.01) and was insensitive to rapamycin treatment. IFN-γ expression was reduced in all lupus T cell subsets (p = 1.0 × 10−5) and also resisted rapamycin. IL-17 expression was increased in CD4+ lupus T cells (SLE: 3.62 ± 0.66%, HC: 2.29 ± 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 ± 0.79%, rapamycin: 2.22 ± 0.60%; p < 0.001). Frequency of regulatory T cells (Tregs) was reduced in SLE (SLE: 1.83 ± 0.25%, HC: 2.97 ± 0.27%; p = 0.0012). Rapamycin inhibited mTORC1 in Tregs and promoted their expansion. Neutralization of IL-17, but not IL-4, also expanded Tregs in SLE and HC subjects. These results indicate that mTORC1 expands IL-4+ DN T and Th17 cells, and contracts Tregs in SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Zheng, W.-P., & Flavell, R. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80240-8 · Cited by 2,384
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Dardalhon, V., Awasthi, A., Kwon, H., Galileos, G., Gao, W., Sobel, R. A., Mitsdoerffer, M., Strom, T. B., Elyaman, W., Ho, I.-C., et al. (2008) · Nature Immunology · doi:10.1038/ni.1677 · Cited by 1,122
CD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000
Bhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798
A role for mammalian target of rapamycin in regulating T cell activation versus anergy
Zheng, Y., Collins, S. L., Lutz, M. A., Allen, A. N., Kole, T. P., Zarek, P. E., & Powell, J. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2163 · Cited by 274
Research works printed but not linked: 66
- Shivakumar, 1989, T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis, J. Immunol., 143, 103, 10.4049/jimmunol.143.1.103 · DOI · Paper page
- Takeuchi, 1984, Cellular mechanism of DNA-specific antibody synthesis by lymphocytes from systemic lupus erythematosus patients, Arthritis Rheum., 27, 766, 10.1002/art.1780270707 · doi:10.1002/art.1780270707
- Sieling, 2000, Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c, J. Immunol., 165, 5338, 10.4049/jimmunol.165.9.5338 · DOI
- Anand, 2002, Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers, Lupus, 11, 493, 10.1191/0961203302lu235oa · DOI
- Rajagopalan, 1990, Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor, Proc. Natl. Acad. Sci. USA, 87, 7020, 10.1073/pnas.87.18.7020 · doi:10.1073/pnas.87.18.7020
- Crispín, 2008, Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys, J. Immunol., 181, 8761, 10.4049/jimmunol.181.12.8761 · DOI · Paper page
- Amel-Kashipaz, 2001, Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus erythematosus, J. Autoimmun., 17, 155, 10.1006/jaut.2001.0525 · DOI
- Horwitz, 1998, Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus, Arthritis Rheum., 41, 838, 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S · DOI
- Akahoshi, 1999, Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus, Arthritis Rheum., 42, 1644, 10.1002/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-L · DOI · Paper page
- Tucci, 2008, Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis, Clin. Exp. Immunol., 154, 247, 10.1111/j.1365-2249.2008.03758.x · DOI
- Min, 2001, Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus, Scand. J. Rheumatol., 30, 159, 10.1080/030097401300162932 · doi:10.1080/030097401300162932
- Tanaka, 1999, Association of the interferon-gamma receptor variant (Val14Met) with systemic lupus erythematosus, Immunogenetics, 49, 266, 10.1007/s002510050492 · doi:10.1007/s002510050492
- Shah, 2010, Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus, Arthritis Res. Ther., 12, R53, 10.1186/ar2964 · DOI · Paper page
- Yang, 2009, Th17 and natural Treg cell population dynamics in systemic lupus erythematosus, Arthritis Rheum., 60, 1472, 10.1002/art.24499 · DOI · Paper page
- Wong, 2008, Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity, Clin. Immunol., 127, 385, 10.1016/j.clim.2008.01.019 · DOI · Paper page
- Mok, 2010, The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus, J. Rheumatol., 37, 2046, 10.3899/jrheum.100293 · DOI
- Doreau, 2009, Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus, Nat. Immunol., 10, 778, 10.1038/ni.1741 · DOI · Paper page
- Crispin, 2003, Quantification of regulatory T cells in patients with systemic lupus erythematosus, J. Autoimmun., 21, 273, 10.1016/S0896-8411(03)00121-5 · DOI · Paper page
- Liu, 2004, Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus, Scand. J. Immunol., 59, 198, 10.1111/j.0300-9475.2004.01370.x · DOI · Paper page
- Miyara, 2005, Global natural regulatory T cell depletion in active systemic lupus erythematosus, J. Immunol., 175, 8392, 10.4049/jimmunol.175.12.8392 · DOI · Paper page
- Mellor-Pita, 2006, Decrease of regulatory T cells in patients with systemic lupus erythematosus, Ann. Rheum. Dis., 65, 553, 10.1136/ard.2005.044974 · DOI
- Bonelli, 2008, Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE), Int. Immunol., 20, 861, 10.1093/intimm/dxn044 · DOI · Paper page
- Lee, 2008, Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus, Rheumatology (Oxford), 47, 789, 10.1093/rheumatology/ken108 · DOI
- Alvarado-Sánchez, 2006, Regulatory T cells in patients with systemic lupus erythematosus, J. Autoimmun., 27, 110, 10.1016/j.jaut.2006.06.005 · DOI · Paper page
- Zhang, 2008, Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus, Ann. Rheum. Dis., 67, 1037, 10.1136/ard.2007.083543 · DOI
- Suárez, 2006, Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids, Ann. Rheum. Dis., 65, 1512, 10.1136/ard.2005.049924 · DOI
- Yan, 2008, Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells, Arthritis Rheum., 58, 801, 10.1002/art.23268 · DOI · Paper page
- Valencia, 2007, Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus, J. Immunol., 178, 2579, 10.4049/jimmunol.178.4.2579 · DOI · Paper page
- Vargas-Rojas, 2008, Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance, Lupus, 17, 289, 10.1177/0961203307088307 · DOI
- Yates, 2008, Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis, Clin. Exp. Immunol., 153, 44, 10.1111/j.1365-2249.2008.03665.x · DOI
- Li, 2011, A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity, Immunity, 34, 541, 10.1016/j.immuni.2011.04.006 · DOI · Paper page
- Jones, 2007, Revving the engine: signal transduction fuels T cell activation, Immunity, 27, 173, 10.1016/j.immuni.2007.07.008 · DOI · Paper page
- Fox, 2005, Fuel feeds function: energy metabolism and the T-cell response, Nat. Rev. Immunol., 5, 844, 10.1038/nri1710 · DOI · Paper page
- Powell, 2010, The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism, Immunity, 33, 301, 10.1016/j.immuni.2010.09.002 · DOI · Paper page
- Delgoffe, 2011, The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2, Nat. Immunol., 12, 295, 10.1038/ni.2005 · DOI · Paper page
- Delgoffe, 2009, The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment, Immunity, 30, 832, 10.1016/j.immuni.2009.04.014 · DOI · Paper page
- Battaglia, 2005, Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells, Blood, 105, 4743, 10.1182/blood-2004-10-3932 · DOI · Paper page
- Kopf, 2007, Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells, Int. Immunopharmacol., 7, 1819, 10.1016/j.intimp.2007.08.027 · DOI · Paper page
- Battaglia, 2006, Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients, J. Immunol., 177, 8338, 10.4049/jimmunol.177.12.8338 · DOI · Paper page
- Kang, 2008, De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR, J. Leukoc. Biol., 83, 1230, 10.1189/jlb.1207851 · DOI
- Fernandez, 2009, Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation, J. Immunol., 182, 2063, 10.4049/jimmunol.0803600 · DOI · Paper page
- Fernandez, 2006, Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus, Arthritis Rheum., 54, 2983, 10.1002/art.22085 · DOI · Paper page
- Tan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 25, 1271, 10.1002/art.1780251101 · DOI · Paper page
- Bombardier, 1992, Derivation of the SLEDAI. A disease activity index for lupus patients, Arthritis Rheum., 35, 630, 10.1002/art.1780350606 · DOI · Paper page
- Richie, 1988, Altered expression of lymphocyte differentiation antigens on phorbol ester-activated CD4+8+ T cells, J. Immunol., 140, 4115, 10.4049/jimmunol.140.12.4115 · doi:10.4049/jimmunol.140.12.4115
- Erard, 1993, Switch of CD8 T cells to noncytolytic CD8-CD4- cells that make TH2 cytokines and help B cells, Science, 260, 1802, 10.1126/science.8511588 · DOI · Paper page
- Crispín, 2009, Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype, J. Immunol., 183, 4675, 10.4049/jimmunol.0901533 · DOI · Paper page
- Lai, 2013, Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus, J. Immunol., 191, 2236, 10.4049/jimmunol.1301005 · DOI
- Zhu, 2004, Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses, Nat. Immunol., 5, 1157, 10.1038/ni1128 · DOI · Paper page
- Wang, 2013, GATA-3 controls the maintenance and proliferation of T cells downstream of TCR and cytokine signaling, Nat. Immunol., 14, 714, 10.1038/ni.2623 · DOI
- Medsger, 2011, GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production, Arthritis Rheum., 63, 1738, 10.1002/art.30489 · DOI
- Yang, 2006, TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity, Proc. Natl. Acad. Sci. USA, 103, 6811, 10.1073/pnas.0602282103 · DOI · Paper page
- Sarbassov, 2004, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton, Curr. Biol., 14, 1296, 10.1016/j.cub.2004.06.054 · DOI · Paper page
- Alexander, 2013, Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus, Ann. Rheum. Dis., 72, 1549, 10.1136/annrheumdis-2012-202216 · DOI
- Golding, 2013, The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus, Arthritis Rheum., 65, 2898, 10.1002/art.38119 · DOI
- Cepika, 2007, Effect of steroids on the frequency of regulatory T cells and expression of FOXP3 in a patient with systemic lupus erythematosus: a two-year follow-up, Lupus, 16, 374, 10.1177/0961203307077990 · doi:10.1177/0961203307077990
- Zhang, 2008, Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells, Nat. Immunol., 9, 1297, 10.1038/ni.1663 · DOI · Paper page
- Zhou, 2008, TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function, Nature, 453, 236, 10.1038/nature06878 · DOI · Paper page
- Fletcher, 2009, CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis, J. Immunol., 183, 7602, 10.4049/jimmunol.0901881 · DOI · Paper page
- Chen, 2011, Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2, Immunity, 34, 409, 10.1016/j.immuni.2011.02.011 · DOI · Paper page
- Pandiyan, 2011, CD4(+)CD25(+)Foxp3(+) regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse Candida albicans Th17 cell infection model, Immunity, 34, 422, 10.1016/j.immuni.2011.03.002 · DOI · Paper page
- Longhi, 2012, Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis, Gastroenterology, 142, 1526, 10.1053/j.gastro.2012.02.041 · DOI
- Itoh, 2011, Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion, Circulation, 124, S187
- Mantel, 2007, GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells, PLoS Biol., 5, e329, 10.1371/journal.pbio.0050329 · DOI · Paper page
- Zeng, 2013, mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function, Nature, 499, 485, 10.1038/nature12297 · DOI · Paper page
- Yurchenko, 2012, Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo, PLoS ONE, 7, e35572, 10.1371/journal.pone.0035572 · DOI
Cited by
Lysosomes as a therapeutic target
Bonam, S. R., Wang, F., & Muller, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0036-1 · Cited by 759
Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective
Moulton, V. R., Suarez-Fueyo, A., Meidan, E., Li, H., Mizui, M., & Tsokos, G. C. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.05.006 · Cited by 469
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases
Perl, A. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 332
Self-citationRegulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Perl, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12756 · Cited by 218
Self-citation
Metadata
- Authors
- Kato, H., & Perl, A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-05-01
- Volume
- 192
- Issue
- 9
- Pages
- 4134-4144
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2097892535
- Cited by
- 165
- References
- 9
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.